ACCPreventionCholesterol精要.pptVIP

* * This slide presents data from a phase III clinical trial of 892 patients with primary hypercholesterolemia randomized to ezetimibe (10 mg) or placebo for 12 weeks. Ezetimibe reduced levels of LDL-cholesterol by 16.9%, compared with an increase of 0.4% with placebo (p0.01). Ezetimibe also significantly (but modestly) increased levels of HDL-C and decreased levels of triglycerides as compared to placebo. No randomized trials powered for clinical outcomes have been published yet. A surrogate endpoint trial, ENHANCE, involved 720 patients with heterozygous familial hypercholesterolemia who